140 related articles for article (PubMed ID: 29251524)
1. Macrophages as an active tumour-targeting carrier of SN38-nanoparticles for cancer therapy.
Huang Z; Sun X; Liu X; Shen Y; Wang K
J Drug Target; 2018; 26(5-6):458-465. PubMed ID: 29251524
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
3. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
Si J; Zhao X; Gao S; Huang D; Sui M
Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer.
Cheng G; Zhang X; Chen Y; Lee RJ; Wang J; Yao J; Zhang Y; Zhang C; Wang K; Yu B
Colloids Surf B Biointerfaces; 2019 Sep; 181():822-829. PubMed ID: 31247407
[TBL] [Abstract][Full Text] [Related]
5. PEGylation of lipophilic SN38 prodrug with DSPE-mPEG
Zeng J; Li C; Duan X; Liu F; Li A; Luo C; Jia L; Gan Y; Yan L; Zheng Y
Drug Deliv; 2019 Dec; 26(1):354-362. PubMed ID: 30909751
[TBL] [Abstract][Full Text] [Related]
6. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
7. Click chemistry-mediated tumor-targeting of SN38-loaded nanoparticles using trastuzumab.
Yoo J; Choi S; Son J; Yi G; Kim E; Koo H
Biochem Biophys Res Commun; 2019 Jul; 515(1):207-213. PubMed ID: 31146921
[TBL] [Abstract][Full Text] [Related]
8. Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7-Ethyl-10-Hydroxycamptothecin.
Liu X; Si J; Zhang Q; Huang Q; Gu D; Yang H; Chen X; Shen Y; Sui M
Adv Healthc Mater; 2018 Apr; 7(7):e1701140. PubMed ID: 29334179
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
[TBL] [Abstract][Full Text] [Related]
10. Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts.
Zhang L; Zhou J; Yan Y; Zhou X; Zhou Q; Du R; Hu S; Ge W; Huang Y; Xu H; Kong Y; Zheng H; Ding Y; Shen Y; Wang W
Cancer Lett; 2019 Nov; 465():36-44. PubMed ID: 31479691
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy.
Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y
J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551
[TBL] [Abstract][Full Text] [Related]
13. Self-assembled nanoparticles comprising aptide-SN38 conjugates for use in targeted cancer therapy.
Kim H; Lee Y; Kang S; Choi M; Lee S; Kim S; Gujrati V; Kim J; Jon S
Nanotechnology; 2016 Dec; 27(48):48LT01. PubMed ID: 27804918
[TBL] [Abstract][Full Text] [Related]
14. Magnetic nanoparticle formulation for targeted delivery of chemotherapeutic irinotecan to lungs.
Kulkarni P; Rajadurai M; Sevilimedu A; Basaveni S; Yellanki S; Medishetti R; Saxena U
Drug Deliv Transl Res; 2018 Oct; 8(5):1450-1459. PubMed ID: 29717474
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
16. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
17. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy.
Lee S; Lee Y; Kim H; Lee DY; Jon S
Biomacromolecules; 2018 Jun; 19(6):2270-2277. PubMed ID: 29712433
[TBL] [Abstract][Full Text] [Related]
18. Empowering hydrophobic anticancer drugs by ultrashort peptides: General Co-assembly strategy for improved solubility, targeted efficacy, and clinical application.
Gao F; Guo J; Liu S; Zhang F; Zhang Y; Wang L
J Colloid Interface Sci; 2024 Aug; 667():119-127. PubMed ID: 38631250
[TBL] [Abstract][Full Text] [Related]
19. A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Qin J; Sun M; Zhen Y; Li J; Wang D
J Drug Target; 2023 Jul; 31(6):623-633. PubMed ID: 37216422
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticulate delivery of irinotecan active metabolite (SN38) in murine colorectal carcinoma through conjugation to poly (2-ethyl 2-oxazoline)-b-poly (L-glutamic acid) double hydrophilic copolymer.
Salmanpour M; Yousefi G; Samani SM; Mohammadi S; Anbardar MH; Tamaddon A
Eur J Pharm Sci; 2019 Aug; 136():104941. PubMed ID: 31136788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
